 On the basis of these results, both nilutamide alone, and particularly the combination of nilutamide and an estrogen, were regarded as effective in terms of producing antiandrogenic effects and feminization in transgender women.Although nilutamide has been found to be effective for transgender hormone therapy, the use of nilutamide in the treatment of prostate cancer and particularly for other indications that are of a less clinically serious nature is now discouraged due to the unique adverse effects of the medication, most importantly a high incidence of interstitial pneumonitis.This is an adverse effect that can progress to pulmonary fibrosis and can potentially be fatal.